The Priority Review

Clinical trials Brief

AmyriAD acquires AD04 Alzheimer's program from ADvantage

AmyriAD announced the acquisition of the AD04 program, a Phase 2b-ready investigational drug targeting neuroinflammation in mild Alzheimer's disease. The program was derived from a 332-patient Phase 2 vaccine study and is planned to enter Phase 2b development under the Innovative Licensing and Access Pathway.

Primary source

Company press release (PR Newswire), November 16, 2026

AmyriAD Therapeutics Acquires AD04 Alzheimer's Program from ADvantage, Further Expanding Its Clinical-Stage Cognition Pipeline

Read the source: AmyriAD Therapeutics Acquires AD04 Alzheimer's Program from ADvantage, Further Expanding Its Clinical-Stage Cognition Pipeline prnewswire.com

Machine-summarized from the source above; not independently reported. How we use automation